Eli Lilly (LLY) Tax Provisions (2009 - 2026)

Eli Lilly (LLY) has reported Tax Provisions for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• Tax Provisions for Q1 2026 came in at $1.5 billion, up 108.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 billion (up 134.51% YoY), and the FY2025 annual result was $5.1 billion, up 143.59% from the prior year.
• Tax Provisions was $1.5 billion for Q1 2026 at Eli Lilly, down from $1.6 billion in the prior quarter.
• Over five years, Tax Provisions peaked at $1.6 billion in Q3 2025 and troughed at $113.8 million in Q3 2022.
• Average Tax Provisions over 5 years is $618.3 million, with a median of $484.6 million recorded in 2023.
• Year-over-year, Tax Provisions sank 32.06% in 2022 and surged 325.83% in 2023.
• Over 5 years, Tax Provisions stood at $158.7 million in 2022, then soared by 100.95% to $318.9 million in 2023, then surged by 97.08% to $628.5 million in 2024, then jumped by 159.11% to $1.6 billion in 2025, then decreased by 10.72% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.